'There is no reason why we should break this business up.'
A terror operative who was the main shooter in the grenade attack on the Punjab police intelligence headquarters in Mohali last year has been arrested from Uttar Pradesh, an official of the National Investigation Agency (NIA) said on Wednesday.
Indian pharmaceutical companies are heavily dependent on China to source fermentation-based active pharmaceutical ingredients and intermediates to manufacture these medicines, but the coronavirus outbreak there has disrupted the supply.
The NCB claimed that the students were both addicts and suppliers of these drugs.
Puri Jagannadh also gave his blood sample.
Companies asked to give data for three batches instead of one; move may lead to significant rise in development cost of generics
In a major crackdown on the nexus between gangsters, terrorist groups and drug smugglers based in foreign countries including Pakistan and Canada, the National Investigation Agency conducted raids at 76 locations across eight states on Tuesday and seized a large cache of arms and ammunition and cash to tune of Rs 1.5 crores.
Which entrepreneur would willingly part with her or his hard-earned money for grasping, self-serving politicians? asks Debashis Basu.
Even smaller companies like Torrent Pharma and Alembic file five to 10 ANDAs every year.
Drugs under exemption make up roughly 95 per cent of the antiretrovirals used by India's AIDS patients
'She got really close, and I was like, oh Miss Universe and me dancing!'
Ranbaxy Laboratories Ltd, India's top drugmaker by sales, said it expected to get US approvals for a paediatric dosage of its generic version of Augmentin, GlaxoSmithKline's blockbuster antibiotic, within a month.\n\n\n\n
Various domestic companies such as Ranbaxy, Wockhardt and Agila Specialities recently came under the US FDA scanner for lapse in manufacturing practices.
The NIA had registered three cases last year following information suggesting that terrorist outfits and their sympathisers abroad were operating as members of organised criminal gangs active in the northern states of India for targeted killings and violent criminal acts.
The Bombay high court on Thursday said it would hear on October 26 the bail plea filed by Aryan Khan, son of superstar Shah Rukh Khan, in connection with a case of seizure of banned drugs on board a cruise ship off the Mumbai coast.
Besides Aryan Khan, the arrested accused are identified as Munmun Dhamecha, Arbaaz Merchant, Ismeet Singh, Mohak Jaswal, Gomit Chopra, Nupur Sarika, and Vikrant Chhokar.
For the poorest 20 per cent of Indians, the expenditure on medicines alone is 85 per cent of what they spend on their health, according to the National Sample Survey.
Animal's violence isn't for the fainted-hearted unless you have an appetite for Korean style mayhem, like Sukanya Verma.
Margaret A Hamburg, the first commissioner of the US Food and Drug Administration (US FDA) to visit India officially, will meet heads of major domestic pharma companies such as Ranbaxy, Wockhardt, Cadila Healthcare and Lupin in New Delhi.
Unlike India, the US is a free-pricing market.
Data also show that several other leading domestic pharma companies have recalled their products from the US
In his appeal in the HC against the special court order, Aryan Khan said the Narcotics Control Bureau's "interpretation and misinterpretation" of the WhatsApp chats collected from his mobile phone was "wrong and unjustified".
The government should take measures to promote innovation and R&D while simplifying regulations for the sector in the upcoming Union Budget, as per pharmaceutical industry bodies. Outlining the wish list for the sector in the upcoming Union Budget, Indian Pharmaceutical Alliance (IPA) secretary general Sudarshan Jain said the domestic pharma industry is currently around $50 billion in size and aspires to grow to around $130 billion by 2030 and $450 billion by 2047. "To achieve this vision, the Union Budget 2023-2024 should help fuel innovation and R&D, which will set the pace for propelling the pharmaceutical industry forward," he told PTI.
The Maharashtra government has capped the prices of N-95, double and triple layer masks for suppliers and private hospitals in the wake of the Covid-19 pandemic, state health minister Rajesh Tope has said.
With all major US export-oriented drug manufacturing plants in the country up for inspection in 2022, some estimates peg that at least 20-30 per cent of the new product launches lined up for the US will be subject to on-site inspection by the US Food and Drug Administration (USFDA). The last two years saw limited physical inspections due to travel restrictions during the pandemic. "Pre-Covid, the frequency and number of inspections of manufacturing plants in India by USFDA had increased significantly," analysts from ICICI Securities Research noted. "With growing ANDA filings, especially for complex products. "We expect this trend to return with the environment normalising," analysts from ICICI Securities Research noted.
The Bharatiya Janata Party's youth wing leader Pamela Goswami was arrested with cocaine from south Kolkata's upscale New Alipore area on Friday, the police said.
Reinvent and innovate will be the key mantra for the Indian pharma industry in the New Year as the 'pharmacy of the world' looks to move from volume to value leadership, amid emerging challenges of inflation and pricing pressures in the global markets. While R&D investment, market competitiveness, regulatory scrutiny, and domestic price regulations are expected to shape the growth of generics and injectable products, concerns such as price control and customs duties on medical equipment will continue to bother the healthcare industry in 2023. The industry believes that in view of India's G20 Presidency, digital health innovation, achieving universal health coverage, improving healthcare infrastructure and delivery will continue to be the key driving factors in 2023.
'The world over, everybody is asking for the same medicines, same APIs, same KSMs.' 'However, there is just one supplier -- China -- for the entire world.'
Speaking to reporters, Raut said, "A special Parliament session should be held. I am demanding this because I have been holding discussons with several prominent leaders since yesterday over the COVID-19 situation in various states. All the leaders accepted that the situation in their states is tense and is going out of control. Only pyres are burning everywhere. There is no space left in cemeteries. It's nothing but total chaos."
GSK is continuing with investigations into the potential source of the NDMA, which is a known environmental contaminant and found in water and foods, including meats, dairy products, and vegetables.
Suit alleges fraud by hiding significant deficiencies in CGMP regulations enforced by US health regulator.
The central drug regulator has issued show cause notices to these two importers and asked to stop the import of rapid test kits based on the observation by the apex health research body Indian Council of Medical Research (ICMR).
India will export anti-malarial drug hydroxychloroquine, high in demand globally, only to foreign governments and not to private companies, as the product is under prohibited or banned category of exports, sources said. Although exports of this medicine is completely banned, India has decided to export this anti-malarial drug in sync with its global commitment to deal with the coronavirus pandemic.
Fund managers said investors remained positive on the pharma manufacturing activity in India, which further strengthened during the Covid-19 period, on account of restrictions imposed on pharma imports from China.
The CoWIN portal will be made available in Hindi and 14 regional languages by next week, while 17 more laboratories will be added to the INSACOG network to monitor the variants of COVID-19, the health ministry said on Monday.
The $66 million (Rs 272.8 crore) Leiner Health Products is likely to sue DRL for the early divorce (the agreement has lasted only four years) from the alliance.
The proposed merger would likely harm future competition
The Bharatiya Janata Party in Maharashtra objected to the pharma executive's grilling by Mumbai police, saying the Shiv Sena-led government in the state was playing politics amid the pandemic.
Terming the situation as scary, Nath also said there was a shortage of Remdesivir injections used in the treatment of coronavirus, and alleged that the key anti-viral drug and oxygen were available only on paper and not in reality.
© 2026 Rediff.com - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances